MX2021013252A - Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos. - Google Patents
Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.Info
- Publication number
- MX2021013252A MX2021013252A MX2021013252A MX2021013252A MX2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A
- Authority
- MX
- Mexico
- Prior art keywords
- circumsporozoite protein
- antibodies binding
- antibodies
- plasmodium circumsporozoite
- plasmodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos dirigidos a los esporozoitos de Plasmodium, en particular a la proteína de circumsporozoito de Plasmodium. La invención también proporciona ácidos nucleicos que codifican para dichos anticuerpos. Además, la invención proporciona el uso de los anticuerpos de la invención en la profilaxis y el tratamiento de la malaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2019/061135 WO2020221451A1 (en) | 2019-04-30 | 2019-04-30 | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
PCT/EP2020/062167 WO2020221910A1 (en) | 2019-04-30 | 2020-04-30 | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013252A true MX2021013252A (es) | 2021-11-17 |
Family
ID=66429360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013252A MX2021013252A (es) | 2019-04-30 | 2020-04-30 | Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230084102A1 (es) |
EP (1) | EP3962513A1 (es) |
JP (1) | JP2022531552A (es) |
KR (1) | KR20220004055A (es) |
CN (1) | CN114206921B (es) |
AU (1) | AU2020266283A1 (es) |
BR (1) | BR112021016341A2 (es) |
CA (1) | CA3130805A1 (es) |
EA (1) | EA202192930A1 (es) |
IL (1) | IL285282A (es) |
MX (1) | MX2021013252A (es) |
SG (1) | SG11202108585QA (es) |
WO (2) | WO2020221451A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021257665A1 (en) * | 2020-06-19 | 2021-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein |
WO2022251585A2 (en) * | 2021-05-28 | 2022-12-01 | David Weiner | Dna antibody constructs for use against plasmodium parasites |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
GB0420634D0 (en) * | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
BRPI0914092B1 (pt) | 2008-10-22 | 2021-08-31 | Institute For Research In Biomedicine | Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo |
WO2011022002A1 (en) * | 2009-08-18 | 2011-02-24 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
CN103611151A (zh) * | 2013-12-06 | 2014-03-05 | 广东药学院 | 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用 |
EA201992434A1 (ru) * | 2017-04-19 | 2020-03-30 | Инститьют Фор Рисерч Ин Байомедисин | Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия |
-
2019
- 2019-04-30 WO PCT/EP2019/061135 patent/WO2020221451A1/en active Application Filing
-
2020
- 2020-04-30 MX MX2021013252A patent/MX2021013252A/es unknown
- 2020-04-30 BR BR112021016341-7A patent/BR112021016341A2/pt unknown
- 2020-04-30 CA CA3130805A patent/CA3130805A1/en active Pending
- 2020-04-30 WO PCT/EP2020/062167 patent/WO2020221910A1/en unknown
- 2020-04-30 JP JP2021561902A patent/JP2022531552A/ja active Pending
- 2020-04-30 KR KR1020217035314A patent/KR20220004055A/ko active Search and Examination
- 2020-04-30 EA EA202192930A patent/EA202192930A1/ru unknown
- 2020-04-30 SG SG11202108585QA patent/SG11202108585QA/en unknown
- 2020-04-30 EP EP20722332.2A patent/EP3962513A1/en active Pending
- 2020-04-30 AU AU2020266283A patent/AU2020266283A1/en active Pending
- 2020-04-30 CN CN202080034143.8A patent/CN114206921B/zh active Active
- 2020-04-30 US US17/607,631 patent/US20230084102A1/en active Pending
-
2021
- 2021-08-01 IL IL285282A patent/IL285282A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL285282A (en) | 2021-09-30 |
EP3962513A1 (en) | 2022-03-09 |
AU2020266283A1 (en) | 2021-09-02 |
SG11202108585QA (en) | 2021-11-29 |
EA202192930A1 (ru) | 2022-02-24 |
CA3130805A1 (en) | 2020-11-05 |
WO2020221910A1 (en) | 2020-11-05 |
WO2020221451A1 (en) | 2020-11-05 |
BR112021016341A2 (pt) | 2021-10-26 |
US20230084102A1 (en) | 2023-03-16 |
CN114206921A (zh) | 2022-03-18 |
JP2022531552A (ja) | 2022-07-07 |
CN114206921B (zh) | 2024-05-14 |
KR20220004055A (ko) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018193063A3 (en) | NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS | |
PH12018501355A1 (en) | Rsv f protein mutants | |
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
CY1124806T1 (el) | Αντισωματα enanti-cd40 και χρησεις αυτων | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
WO2015109124A3 (en) | Immunomodulatory agents | |
MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
MX2018011425A (es) | Construcciones de anticuerpos de adn y método para utilizarlas. | |
WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
MX2016010259A (es) | Construcciones de variantes de sirp-alfa y sus usos. | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
WO2019014360A8 (en) | POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF | |
MX2021013252A (es) | Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos. | |
NZ722518A (en) | Il-21 antibodies | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
PH12018501739A1 (en) | Antibodies for il-17c | |
MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
WO2018170236A9 (en) | CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS | |
MX2018014253A (es) | Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria. | |
MX2022000393A (es) | Metodo. | |
EA201992840A3 (ru) | Конструкции варианта sirp-альфа и их применение |